Identification of phthalates in medications and dietary supplement formulations in the United States and Canada

Environmental Health Perspectives

Volumn 120, Issue 3, 2012, Pages 379-384

  Kelley, Katherine E ^a   Hernández Díaz, Sonia ^b   Chaplin, Erica L ^a   Hauser, Russ ^b   Mitchell, Allen A ^a  

^a BOSTON UNIVERSITY   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Coating; Dietary supplements; Excipients; Medications; Phthalates

Indexed keywords

ACEBUTOLOL; CARBAMAZEPINE; CELLACEFATE; CYCLOBENZAPRINE; DIDANOSINE; DILTIAZEM; ERYTHROMYCIN; GALANTAMINE; HYPROMELLOSE PHTHALATE; ISOSORBIDE; KETOPROFEN; MESALAZINE; MORPHINE SULFATE; NON PRESCRIPTION DRUG; NU KETOPROFEN E; PANCRELIPASE; PHTHALIC ACID DERIVATIVE; PHTHALIC ACID DIETHYL ESTER; POLYVINYL ACETATE PHTHALATE; POTASSIUM CHLORIDE; PRESCRIPTION DRUG; PROCHLORPERAZINE; PROCHLORPERAZINE MALEATE; PROFENAMINE; PROPRANOLOL; RANITIDINE; SALAZOSULFAPYRIDINE; THEOPHYLLINE; THIOPROPERAZINE METHANESULFONATE; TRIMIPRAMINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALPROATE SEMISODIUM; VALPROIC ACID; VIDEC EC;

ARTICLE; CANADA; CHEMICAL ANALYSIS; DIET SUPPLEMENTATION; DRUG MARKETING; INTERNET; PRESCRIPTION; PRIORITY JOURNAL; UNITED STATES;

CANADA; DELAYED-ACTION PREPARATIONS; DIETARY SUPPLEMENTS; ENVIRONMENTAL EXPOSURE; EXCIPIENTS; NONPRESCRIPTION DRUGS; PHARMACEUTICAL PREPARATIONS; PHTHALIC ACIDS; PRESCRIPTION DRUGS; UNITED STATES;

ANIMALIA;

EID: 84857757174     PISSN: 00916765     EISSN: 15529924     Source Type: Journal    
DOI: 10.1289/ehp.1103998     Document Type: Article

References (46)

1. Abbott Laboratories. 2011. Creon Delayed-Release Capsules. North Chicago, IL:Abbott Laboratories. Available: http://www.rxabbott.com/pdf/creon_PI.pdf [accessed 23 January 2012].
2. Allen LV, Popovich NG, Ansel HC, eds. 2005. Ansel's Pharmaceutical Dosage Forms and Drug Delivery Systems. 8th ed. Baltimore, MD:Lippincott Williams & Wilkins.
3. Apotex Inc. 2011. DILT-CD (diltiazem hydrochloride extended-release capsules, USP). Toronto, Ontario, Canada:Apotex Inc. Available: http://www.apotex.com/us/en/products/downloads/pil/dilt_ercp_ins.pdf [accessed 11March 2011].
4. Astra Aktiebolag, et al. v. Andrx Pharmaceuticals Inc., etal. 2002. Case no. 222 F. Supp. 423 (S.D.N.Y. 2002). U.S. District Court, Southern District of New York, 11 October.
5. Berna Biotech Ltd. 2006. Vivotif (Typhoid Vaccine Live Oral Ty21a). Coral Gables, FL. Available: http://www.fda.gov/downloads/Biologics Blood Vaccines/Vaccines/Approved Products/UCM142807.pdf [accessed 11March 2011].
6. BTA Pharmaceuticals Inc. 2010. Cardizem CD (Diltiazem Hydrochloride) Capsule. Available: http://dailymed.nlm.nih.gov/dailymed/drug Info.cfm?id=34903 [accessed 11March 2011].
7. Canadian Pharmaceutical Association. 1995-2006. CPS: Compendium of Pharmaceuticals and Specialties. Ottowa, Ontario, Canada:Canadian Pharmaceutical Association.
8. Corporacion Informasa. 2010. Omesec-Omeprazole Capsule, Delayed Release. Available: http://dailymed.nlm.nih.gov/dailymed/fda/fda Drug Xsl.cfm?id=18604&type=display [accessed 11March 2011].
9. Crucell Switzerland LTD. 2010. Vivotif: Thyphoid Vaccine Live Oral Attenuated TY21A. Available: http://www.crucellvaccinescanada.com/pdf/100316_Product_Monograph_Vivotif_Canada_def_hc.pdf [accessed 19 January 2012].
10. DSHEA. 1994. Dietary Supplement Health and Education Act of 1994. Public Law 103-417. Available: http://ods.od.nih.gov/about/dshea_wording.aspx [accessed 19January 2012].
11. FDA (Food and Drug Administration). 2009. New Dietary Ingredients. Available: http://www.gpo.gov/fdsys/pkg/USCODE-2010-title21/pdf/USCODE-2010-title21-chap9-subchap IV-sec350b.pdf [accessed 19January 2012].
12. FDA (Food and Drug Administration). 2010a. FDA Drug Applications for Over-the-Counter Drugs. Available: http://www.fda.gov/drugs/developmentapprovalprocess/howdrugsaredevelopedandapproved/approvalapplications/over-the-counterdrugs/default.htm [accessed 11March 2011].
13. FDA (Food and Drug Administration). 2010b. Inactive Ingredient Search for Approved Drug Products: Frequently Asked Questions. Available: http://www.fda.gov/Drugs/Information On Drugs/ucm080123.htm [accessed 11 March 2011].
14. FDA (Food and Drug Administration). 2011a. Current Good Manufacturing Practice in Manufacturing, Processing, Packing, or Holding of Drugs; General. Definitions. 21CFR210.3. Available: http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=210.3 [accessed 19January 2012].
15. FDA (Food and Drug Administration). 2011b. Drugs@FDA: FDA Approved Drug Products. Available: http://www.accessdata.fda.gov/scripts/cder/drugsatfda/ [accessed 11 March 2011].
16. Foster P. 2005. Mode of action: impaired fetal Leydig cell function-effects on male reproductive development produced by certain phthalate esters. Crit Rev Toxicol 35(8-9):713-719.
17. Hauser R, Duty S, Godfrey-Bailey L, Calafat AM. 2004. Medications as a source of human exposure to phthalates. Environ Health Perspect 112:751-753.
18. Health Canada. 2011a. Drug Product Database. Available: http://www.hc-sc.gc.ca/dhp-mps/prodpharma/databasdon/index-eng.php [accessed 11 March 2011].
19. Health Canada. 2011b. Licensed Natural Health Products Database. Available: http://www.hc-sc.gc.ca/dhp-mps/prodnatur/applications/licen-prod/lnhpd-bdpsnh-eng.php [accessed 11March 2011].
20. Hernández-Díaz S, Mitchell AA, Kelley KE, Calafat AM, Hauser R. 2009. Medications as a potential source of exposure to phthalates in the U.S. population. Environ Health Perspect 117:185-189.
21. Howdeshell K, Rider C, Wilson V, Gray LJ. 2008. Mechanisms of action of phthalate esters, individually and in combination, to induce abnormal reproductive development in male laboratory rats. Environ Res 108(2):168-179.
22. Keller BO, Davidson AGF, Innis SM. 2009. Phthalate metabolites in urine of CF patients are associated with use of enteric-coated pancreatic enzymes. Environ Toxicol Pharmacol 27(3):424-427.
23. Mitchell JF. 2011. Oral dosage forms that should not be crushed. Available: http://www.ismp.org/tools/donotcrush.pdf [accessed 11March 2011].
24. Mylan Pharmaceuticals Inc. 2006. Diltiazem hydrochloride extended-release capsule. Canonsburg, PA:Mylan Pharmaceuticals Inc. Available: http://dailymed.nlm.nih.gov/dailymed/drug Info.cfm?id=44562 [accessed 20 January 2012].
25. Mylan Pharmaceuticals Inc. 2010a. Verapamil Hydrochloride Capsule, Extended Release. Canonsburg, PA:Mylan Pharmaceuticals Inc. Available: http://dailymed.nlm.nih.gov/dailymed/drug Info.cfm?id=21863 [accessed 11March 2011].
26. Mylan Pharmaceuticals Inc. 2010b. Verapamil Hydrochloride Capsule, Extended Release (PM). Available: http://dailymed.nlm.nih.gov/dailymed/drug Info.cfm?id=33906 [accessed 11 March 2011].
27. NLM (National Library of Medicine). 2011a. Daily Med. Available: http://dailymed.nlm.nih.gov [accessed 11March 2011].
28. NLM (National Library of Medicine). 2011b. Dietary Supplements Labels Database. Available: http://dietarysupplements.nlm.nih.gov [accessed 11March 2011].
29. Osterberg RE, See NA. 2003. Toxicity of excipients-a food and drug administration perspective. Int J Toxicol 22(5):377-380.
30. Reed Technology and Information Services Inc. 2011. Label Data Plus. Available: http://www.labeldataplus.com/[accessed 11March 2011].
31. Rowe RC, Sheskey PJ, Quinn ME, eds. 2009. Handbook of Pharmaceutical Excipients. 6th ed. Washington, DC:American Pharmaceutical Association.
32. Shire LLC v. Nostrum Pharmaceuticals Inc. etal. 2008. Case No. 3:08-cv-03309. District Court of New Jersey, 2 July.
33. Silva MJ, Barr DB, Reidy JA, Malek NA, Hodge CC, Caudill SP, et al. 2004. Urinary levels of seven phthalate metabolites in the U.S. population from the National Health and Nutrition Examination Survey (NHANES) 1999-2000. Environ Health Perspect 112:331-338.
34. Solvay Pharmaceuticals Inc. 2006. Creon Minimicrospheres. Marietta, GA:Solvay Pharmaceuticals Inc. Available: http://www.creon-us.com/Content/assets/pdf/CREON%205,%2010,%2020%20Prescribing%20Information.pdf [accessed 23 January 2012].
35. Steinberg M, Silverstein I. 2003. The use of unallowed excipients. Int J Toxicol 22(5):373-375.
36. Swan SH. 2008. Environmental phthalate exposure in relation to reproductive outcomes and other health endpoints in humans. Environ Res 108(2):177-184.
37. Thomson Healthcare. 1995-2010a. Physicians' Desk Reference. Montvale, NJ:Thomson Healthcare.
38. Thomson Healthcare. 1995-2010b. Physicians' Desk Reference for Nonprescription Drugs, Dietary Supplements, and Herbs. Montvale, NJ:Thomson Healthcare.
39. Thomson PDR. 2006. Drugs that should not be crushed. In: 2006 Red Book: Pharmacy's Fundamental Reference. 110th ed. Montvale, NJ:Thomson PDR, 40-44.
40. U.S. Pharmacopeial Convention. 2009. Labeling of inactive ingredients. In: The United States Pharmacopeia-National Formulary. USP 32/NF 27. Rockville, MD:U.S. Pharmacopeial Convention, 599.
41. Warner Chilcott Pharmaceuticals Inc. 2010a. Asacol (Mesalamine) Delayed-Release Tablets. Mason, OH:Warner Chilcott Pharmaceuticals Inc.
42. Warner Chilcott Pharmaceuticals Inc. 2010b. Asacol HD (Mesalamine) Delayed-Release Tablets. Mason, OH:Warner Chilcott Pharmaceuticals Inc.
43. Watson Pharma Inc. 2008. Diltia XT (Diltiazem Hydrochloride) Capsule, Extended Release. Available: http://dailymed.nlm.nih.gov/dailymed/drug Info.cfm?id=8656 [accessed 11 March 2011].
44. Wockhardt USA LLC. 2007. Ranitidine Tablet, Coated, 150mg. Available: http://dailymed.nlm.nih.gov/dailymed/drug Info.cfm?id=17165 [accessed 11 March 2011].
45. Wockhardt USA LLC. 2008. Ranitidine Tablet, Coated, 75mg. Available: http://dailymed.nlm.nih.gov/dailymed/drug Info.cfm?id=17159 [accessed 11 March 2011].
46. Wockhardt USA LLC. 2009. Ranitidine (Ranitidine Hydrochloride) Tablet. Parsippany, NJ:Wockhardt USA LLC. Available: http://dailymed.nlm.nih.gov/dailymed/drug Info.cfm?id=15325 [accessed 11 March 2011].